ABOUT US

Renaissance of Medicine

ABOUT US

Renaissance of Medicine

OVERVIEW

MediciBIO is established to develop novel gene therapy technology by converging knowledge in the fields of new drug development, drug delivery, and genetic biotechnology.


Nowadays, “Medici effect” means “a phenomenon in which innovative ideas explode at the intersection of different ideas”, emphasizing the importance of innovation through converging technologies.


In line with the big trend of biopharmaceuticals on gene therapy, the aim of MediciBIO is to preempt an innovative original technology for gene therapy through integration of genetic biotechnology, innovative drug delivery system, and robust CMC strategy.


MediciBIO develops innovative new drugs against genetic and rare diseases and core platform technologies for efficient delivery of gene therapeutics with a vision to become a global specialty company in the gene therapy market that is estimated to expand over the next 30 years.

VISION

MediciBIO aims to grow as a global biotechnology company through the gene therapy platform technology and the development of innovative new drug for intractable genetic diseases.

Platform Technology Development

MediciBIO develops a core platform technology for efficient therapeutic delivery of siRNA and ASO (anti-sense oligonucleotides) as well as mRNA and samRNA (self-amplifying mRNA) to supply the cutting edge series of gene carrier products.

New Drug Development

MediciBIO seeks to provide new therapeutic means to patients for their healthy living by developing innovative medicines including first-in-class and orphan drugs against genetic and rare diseases, which have no current treatment in the fields of ophthalmology, cancer and neurology.

\

OVERVIEW

MediciBIO is established to develop novel gene therapy technology by converging knowledge in the fields of new drug development, drug delivery, and genetic biotechnology.


Nowadays, “Medici effect” means “a phenomenon in which innovative ideas explode at the intersection of different ideas”, emphasizing the importance of innovation through converging technologies.


In line with the big trend of biopharmaceuticals on gene therapy, the aim of MediciBIO is to preempt an innovative original technology for gene therapy through integration of genetic biotechnology, innovative drug delivery system, and robust CMC strategy.


MediciBIO develops innovative new drugs against genetic and rare diseases and core platform technologies for efficient delivery of gene therapeutics with a vision to become a global specialty company in the gene therapy market that is estimated to expand over the next 30 years.

VISION

MediciBIO aims to grow as a global biotechnology company through the gene therapy platform technology and the development of innovative new drug for intractable genetic diseases.

Platform Technology Development

New Drug Development

MediciBIO develops a core platform technology for efficient therapeutic delivery of siRNA and ASO (anti-sense oligonucleotides) as well as mRNA and samRNA (self-amplifying mRNA) to supply the cutting edge series of gene carrier products.

MediciBIO seeks to provide new therapeutic means to patients for their healthy living by developing innovative medicines including first-in-class and orphan drugs against genetic and rare diseases with no current treatment in the fields of ophthalmology, cancer and neurology.

Addressㅣ  A-2207, 184, Jungbu-daero, Giheung-gu, Yongin-si, 

                    Gyeonggi-do, 17095 Republic of Korea

Telㅣ  +82-31-895-6707    Faxㅣ  +82-70-8676-6706

Copyright © MediciBIO Co.,LTD. All rights reserved. 

Headquarter   A-2207, 184, Jungbu-daero, Giheung-gu, Yongin-si, Gyeonggi-do, 17095 Republic of Korea

Branch Office  A-13, 3rd Floor, 194-25, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 28160 Republic of Korea

Tel ㅣ +82-31-895-6707     Fax ㅣ +82-70-8676-6706    Email ㅣ biz@medicibio.com

Copyright © MediciBIO Co.,LTD. All rights reserved.